公开(公告)号：US09949979B2

公开(公告)日：2018-04-24

申请号：US14365512

申请日：2012-12-14

Applicant: NOVARTIS AG

Inventor： Nigel Graham Cooke ,  Paulo Antonio Fernandes Gomes Dos Santos ,  Pascal Furet ,  Christina Hebach ,  Klemens Hoegenauer ,  Gregory Hollingworth ,  Christoph Kalis ,  Ian Lewis ,  Alexander Baxter Smith ,  Nicolas Soldermann ,  Frederic Stauffer ,  Ross Strang ,  Frank Stowasser ,  Nicola Tuffilli ,  Anette Von Matt ,  Romain Wolf ,  Frederic Zecri

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/517 ,  A61K31/551 ,  C07D401/14 ,  C07D413/14 ,  C07D401/04 ,  C07D403/04 ,  C07D239/74 ,  C07D487/08

CPC classification number: A61K31/519 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  C07D239/74 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D487/08 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414

Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.